Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Nontuberculous mycobacteria Stories

2013-07-10 12:07:58

Sexual reproduction is costly to those organisms that depend on it, like humans. For starters, only half of the population can bear offspring and the other half has to work hard to make sure they're included in the future gene pool. The payoff is that sexual reproduction allows the mixing of parental genomes to generate potentially beneficial new combinations of gene variants that had not previously coexisted on the same strand of DNA, or to separate beneficial mutations from detrimental...

2012-12-13 08:26:43

MONMOUTH JUNCTION, N.J., Dec. 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for patients with high unmet need who are battling serious orphan lung diseases, today announced that the Company will be participating in the 31(st) Annual J.P. Morgan Healthcare Conference from January 7-10, 2013 at the Westin St. Francis Hotel in San Francisco. Will Lewis, Insmed's President...

2012-11-13 08:34:56

MONMOUTH JUNCTION, N.J., Nov. 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's CLinical Evaluation of ARIKACE (CLEAR-108) phase 3 European and Canadian registrational study of ARIKACE® (liposomal amikacin for inhalation) for Cystic Fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) lung infections has now enrolled over 300...

2012-11-12 08:27:34

MONMOUTH JUNCTION, N.J., Nov. 12, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that Will Lewis, President and Chief Executive Officer, will be presenting a corporate overview at the Lazard Capital Markets 9(th) Annual Healthcare Conference and the Oppenheimer 23(rd) Annual Healthcare Conference. Mr. Lewis will present at the Lazard Capital Markets 9(th...

2012-11-07 08:26:58

MONMOUTH JUNCTION, N.J., Nov. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the appointment of Andrew Drechsler to the position of Chief Financial Officer. Mr. Drechsler will assume the role of Principal Financial and Accounting Officer as of November 8, 2012. Mr. Drechsler offers 15 years of financial and operational leadership experience in both public...

2012-10-24 07:31:08

MONMOUTH JUNCTION, N.J., Oct. 24, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, will host a conference call on Wednesday, November 7(th), 2012, at 8:30 AM ET, to discuss its financial results for the third quarter of 2012. Insmed intends to issue its quarterly financial results press release before the market opens on November 7(th). To...

2012-09-28 02:24:51

MONMOUTH JUNCTION, N.J., Sept. 28, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced that it has priced a direct public offering of approximately 6.3 million shares of its Common Stock to certain affiliates of Ayer Capital, RA Capital and Quaker Partners, at a price of $4.07 per share, which was the consolidated closing bid price...

2012-09-11 02:28:40

MONMOUTH JUNCTION, N.J., Sept. 11, 2012 /PRNewswire/ -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced the appointment of Will Lewis as President and Chief Executive Officer, effective immediately. Mr. Lewis has also been appointed to the Company's Board of Directors. He succeeds Tim Whitten, who has resigned as President and Chief Executive Officer...

2012-08-23 10:56:29

Autoantibody may cause susceptibility to opportunistic infections A clinical study led by National Institutes of Health investigators has identified an antibody that compromises the immune systems of HIV-negative people, making them susceptible to infections with opportunistic microbes such as nontuberculous mycobacteria (NTM). In this study conducted at hospitals in Thailand and Taiwan, the researchers found that the majority of study participants with opportunistic infections made an...

2012-06-27 02:27:20

MONMOUTH JUNCTION, N.J., June 27, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease entitled TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial). "The prevalence of this debilitating chronic disease continues to grow, and...


Latest Nontuberculous mycobacteria Reference Libraries

0_da8e53266fdcbd2830a775ec887963be
2011-04-25 15:36:41

Mycobacterium leprae, mostly found in warm tropical countries, is a bacterium that causes leprosy (Hansen's disease). It is an intracellular, pleomorphic, acid-fast bacterium. M. leprae is an aerobic rod-shaped surrounded by the characteristic waxy coating unique to mycobacteria tuberculosis. Due to its thick waxy coating, M. leprae stains with a carbol fuscin rather than with the traditional Gram stain. Gerhard Armauer Hansen first discovered it in 1873. It was the first bacterium to be...

More Articles (1 articles) »